Search results
Study highlights need for cell-type-specific therapies in treatment of HIV
Medical Xpress· 2 days agoResearchers from the University of Illinois have demonstrated the importance of cell-type-specific...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 5 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma ...